Davide Bonazzi
Illustrator
From this contributor
Company on brink takes psilocybin to trial for fragile X syndrome
The phase 2A trial has its detractors despite positive animal results and is being sponsored by a company that is struggling financially.
Company on brink takes psilocybin to trial for fragile X syndrome
Explore more from The Transmitter
Language development during the first 1,000 days; and more
Here is a roundup of autism-related news and research spotted around the web for the week of 9 November.
Language development during the first 1,000 days; and more
Here is a roundup of autism-related news and research spotted around the web for the week of 9 November.
What ‘Brain Flows’ gets right
Michael W. Cole’s new book makes a convincing case that the dynamic movement of signals underpins just about everything the brain does, though it misses mention of relevant theoretical and single-cell work.
What ‘Brain Flows’ gets right
Michael W. Cole’s new book makes a convincing case that the dynamic movement of signals underpins just about everything the brain does, though it misses mention of relevant theoretical and single-cell work.
Amid funding uncertainty, graduate neuroscience programs in the U.S. adapt
The Transmitter surveyed 50 graduate program directors to learn how they’re faring. Securing labs for new students is one of the greatest concerns.
Amid funding uncertainty, graduate neuroscience programs in the U.S. adapt
The Transmitter surveyed 50 graduate program directors to learn how they’re faring. Securing labs for new students is one of the greatest concerns.